Portrait of a senior woman standing outdoors on a holiday. Senior woman wearing a backpack and jacket standing during a trekking trip.

Bringing hope through science

Oncopeptides AB (publ) is a biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers. We are science driven, entrepreneurial, and committed to bringing innovation to our patients. Our vision is to bring hope to patients through passionate people, innovative science and transformative drugs.

Read more about Oncopeptides

Invitation to presentation of the Q1 report 2025

May 13, 2025 – Oncopeptides AB will publish the report for the first quarter 2025, at 08:00 CET on May 15, 2025. Investors, financial analysts, and media are invited to participate in a webcast and a subsequent Q&A session on May 15 at 09:00 CET.

More information and the link to the webcast

Notice to Annual General Meeting at Oncopeptides AB (publ)

April 16, 2025 – The shareholders in Oncopeptides AB are hereby given notice to attend the Annual General Meeting to be held at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm, Sweden on Thursday 22 May 2025 at 10.00 a.m.

More information and Q&A regarding Board Changes Ahead

Company news

Notice to Annual General Meeting at Oncopeptides AB (publ)

April 16, 2025

The shareholders in Oncopeptides AB are hereby given notice to attend the Annual General Meeting to be held at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm, Sweden on Thursday 22 May 2025 at 10.00 a.m.

Read more

Oncopeptalks – first order in Italy and Q4 report

March 13, 2025

In the latest episode of Oncopeptalks, David and Sofia discuss the recent news of a first Pepaxti order in Italy and some of the questions following the Q4 report.

Read more

Oncopeptides receives first order of Pepaxti in Italy

March 11, 2025

Read more

Science news

New Real-World Data support effectiveness and tolerability of Pepaxti in heavily pretreated Multiple Myeloma patients

April 16, 2025

Oncopeptides announces the publication of new real-world data that further support the effectiveness and tolerability of melflufen, branded in Europe as Pepaxti, in patients with relapsed, refractory multiple myeloma (RRMM).

Read more

FDA removes clinical hold of Oncopeptides’ pipeline drug OPD5

April 1, 2025

Oncopeptides today announces the U.S. Food and Drug Administration (FDA) has lifted the clinical hold previously placed on Oncopeptides’ next-gen drug OPD5. 

Read more

Strong real-world efficacy and safety data with Pepaxti published in the European Journal of Haematology

February 25, 2025

Oncopeptides AB today announces that a new real-world study on melflufen (melphalan flufenamide, branded in Europe as Pepaxti) plus dexamethasone in patients with relapsed, refractory multiple myeloma (RRMM) has been published in the peer-reviewed journal European Journal of Haematology.

Read more

Investor news

Invitation to presentation of the Q1 report 2025

May 13, 2025

Oncopeptides AB will publish the report for the first quarter 2025, at 08:00 CET on May 15, 2025. Investors, financial analysts, and media are invited to participate in a webcast and a subsequent Q&A session on May 15 at 09:00 CET.

Read more

Oncopeptalks – a mixed bag of topics

April 11, 2025

Read more

Oncopeptides presented at the Redeye event Commercialization in Life Science

March 21, 2025

CEO Sofia Heigis recently presented the company at the Redeye event followed by a Q&A.

Read more

All Company news

All Science news

All Investor news

Press release - May 13, 2025

Invitation to presentation of the Q1 report 2025

Read press release

Latest press releases

All press releases

Released April 28, 2025

Oncopeptides publishes the 2024 Annual Report

Read report

Download

“2024 was a transformative year for Oncopeptides as we continued our journey toward sustainable growth and expanded access to Pepaxti.”

CEO Sofia Heigis

For further information, please contact:

David Augustsson
Director Corporate Affairs
david.augustsson@oncopeptides.com
+46 762 29 38 68

 

Oncopeptides AB Interim Report Q1 2025 will be published May 15, 2025

Upcoming events

2025-04-15 - 2025-05-14

Silent period

Other

2025-05-15

Interim Report Q1 2025

Report

2025-05-22

General Annual Meeting

Meeting

Full calendar
Senior Hispanic man in wheelchair, with adult son

Vision of Oncopeptides

”Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”

Read more about Oncopeptides

Oncopeptides value words inside the logotype

Cultures & Values

We are a science driven, entrepreneurial company, committed to bringing innovation to patients with an unmet medical need, and improving their lives.

Read more

Journey of innovation

Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden’s leading cancer researchers and cancer research institutions.

Read more about our history

Oncopeptides via e-mail

CEO Sofia Heigis - Oncopeptides AB

Released February 27, 2025

Oncopeptides publishes year-end report 2024

Read report

Download

“35% percent quarterly growth, Italian reimbursement and alignment on regulatory pathway in Japan“

CEO Sofia Heigis

 

See the Webcast

The presenation in PDF

For further information, please contact:

David Augustsson
Director Corporate Affairs
david.augustsson@oncopeptides.com
+46 762 29 38 68

 

Oncopeptides AB Interim Report Q1 2025 will be published May 15, 2025